RE:CCbepando,
I was also intrigued by PL's response to the question around linkage between IPF and the lung remodelling news release on Monday. He said someting to the effect that the prospects of 4050 in the lung goes well beyond IPF.
I notice the pivotal addon trial for 4050 in IPF discussed the FDA last fall is once again not listed as an upcoming trial (page 12 of the presentation). It has come and gone from the list in the last couple of presentations. My guess is something has changed here and hopefully for the better. We will see next Monday.
GLA and IMHO